CPIM
TBPH icon

Columbia Partners Investment Management’s Theravance Biopharma TBPH Stock Holding History

Columbia Partners Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-20,750
Closed -$751K – 311
2016
Q3 		$751K Buy
+20,750
New +$578K 0.06% 259

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Columbia Partners Investment Management's TBPH Position: Q4 2016 in Review

Columbia Partners Investment Management sold out of Theravance Biopharma (TBPH) in Q4 2016, closing a stake of 20,750 shares — an estimated $751K sold.

Columbia Partners Investment Management first reported a position in TBPH in Q3 2016 and held it in 1 quarter. The position peaked at $751K in Q3 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

  • Columbia Partners Investment Management reported no remaining Theravance Biopharma position as of Q4 2016 after selling out during the quarter.
  • Columbia Partners Investment Management sold 20,750 Theravance Biopharma shares in Q4 2016, an estimated $751K.
  • Columbia Partners Investment Management first reported a position in Theravance Biopharma in Q3 2016 and held it in 1 quarter.
  • Columbia Partners Investment Management's Theravance Biopharma position peaked at $751K in Q3 2016.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on Columbia Partners Investment Management's 13F filing for Q4 2016, filed 13 Feb 2017.